To the Editor,

many patients infected by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) reported olfactory and taste dysfunction \[[@bb0005],[@bb0010]\]. Anosmia and hypogeusia were recognized as presenting clinical symptoms of Coronavirus Disease 2019 (COVID-19) \[[@bb0015]\]. Sungnak et al. \[[@bb0020]\] investigated the expression of SARS-CoV-2 entry-associated genes in multiple tissues from healthy human donors. They found that these genes were expressed in nasal epithelial cells, highlighting the cells\' potential role in initial viral infection. A multicenter European study enrolling 417 mild-to-moderate COVID-19 patients found olfactory/taste alterations in \>80% of cases \[[@bb0025]\]. The early follow up of these patients (14 days) showed that olfactory dysfunction persisted in 56% of cases \[[@bb0025]\]. In the present investigation, our primary aim was to evaluate olfactory/taste alterations one month after COVID-19 diagnosis. The secondary aim was to search clinical characteristics associated with the persistence of sensory dysfunctions.

Three international ethics committees (HAP2020--011; CHUSP20032020; EpiCURA-2020-2303) and the Italian committee of Veneto region (protocol n°: 0171064) approved the study protocol. Informed consent was obtained verbally during telephone interviews. Inclusion criteria were: i) ≥ 18 years old; ii) laboratory-confirmed COVID-19 infection (reverse transcription polymerase chain reaction on nasopharyngeal swab) at least one month before inclusion; iii) olfactory and/or taste dysfunction. Exclusion criteria: i) patients with olfactory/gustatory alterations before the epidemic; ii) patients who were in the intensive-care unit at the time of the study (due to their health status). Thus, we included mild-to-moderate COVID-19 patients, defined as patients without need of intensive cares.

During the telephonic survey, we used the questionnaire proposed by the COVID-19 Task Force of YO-IFOS^5^. We classified the outcome of olfactory/taste dysfunction as persistence (1) or resolution (0). We used Fisher exact test and Mann-Whitney *U* test as needed. For significant association at Fisher exact test, we calculated odds ratio (OR) and 95% confidence interval (CI). A multivariate logistic regression was calculated, adding only the clinical parameters with a p value ≤0.05, as disclosed by Fisher exact test at univariate analysis. The results were expressed as ORs, p values, and 95% CI. A p value \<0.05 was considered significant.

We included 121 COVID-19 patients with olfactory and/or taste alterations; the mean follow up time from diagnosis was 38.2 days (standard deviation \[SD\] 3.0 days). [Table 1](#t0005){ref-type="table"} summarized clinical characteristics and treatments. General symptoms resolved in all but 5 patients (3 had dry cough and 2 fatigue). Persistence of sensory dysfunction was reported by 26 subjects (21.5%). The duration of smell and gustatory symptoms was significantly longer (p \< 0.00001; Mann-Whitney *U* test) in patients with persistence (mean 39.1 days) when compared with those with resolution (mean 15.6 days). At univariate analysis, patients without fever (OR 6.26; 95% CI = 2.45--15.99; p = 0.0001) and with olfactory/taste alterations before general symptoms (OR 3.36; 95% CI = 1.32--8.59; p = 0.01) were at higher risk of persistent complaints. Only absence of fever (OR 5.29; 95% CI = 2.02--13.89; p = 0.0007) was an independent prognostic factor (olfactory and taste dysfunction before general symptoms; OR 2.38; 95% CI = 0.86--6.58; p = 0.09) at multivariate analysis.Table 1Clinical characteristics and therapy of COVID-19 patients with resolved or persistent olfactory/taste alterations.Table 1TotalResolutionPersistencep value[⁎](#tf0005){ref-type="table-fn"}N.° of patients1219526Female/male72/4955/4017/90.65Mean age46.748.246.10.9  SymptomsAnosmia/Hyposmia50/6442/468/180.37Ageusia/Hypogeusia45/7131/5914/120.11Nasal Congestion yes/no19/10214/815/210,55Rhinorrhoea yes/no27/9420/757/190,6Fever yes/no89/3278/1711/150.0002Cough yes/no76/4558/3718/80.5Fatigue yes/no83/3863/3220/60.35Myalgia yes/no46/7532/6314/120.07  Relationship between onset of olfactory/taste dysfunction and general symptomsBefore/together or after general symptoms28/9317/7811/150.01  Associated chronic medical illnessAllergic rhinitis yes/no31/9027/684/220.21Hypertension yes/no15/10612/833/231.0Asthma yes/no11/1108/873/230.7Diabetes yes/no3/1183/920/261.0  TherapyNasal saline irrigations yes/no48/7342/536/200.07Nasal steroids yes/no39/8229/6610/160.49Hydroxychloroquine yes/no7/1147/880/260.34[^1]

Previous studies have already shown the ability of SARS coronavirus to cause neuronal death in mice by invading the brain via the nose close to the olfactory epithelium \[[@bb0005]\]. We could hypothesize that SARS-CoV-2 has a similar behavior, given the well-known genetic similarity with other coronaviruses \[[@bb0015]\]. In a recent clinical study, Vaira et al. \[[@bb0030]\] considering 72 COVID-19 cases, found in 34% a persistence of alterations in taste and olfaction. Also in our series of 121 COVID-19 patients olfactory and taste alterations lasted more than one month in 21.5% of cases. However, most of patients reported resolution of symptoms after a mean of 15 days, and this confirmed the data from previous survey \[[@bb0025]\]. In the present investigation, absence of fever was an independent prognostic factor of persistent olfactory/taste dysfunction in COVID-19 patients. A survey on 1420 COVID-19 patients found that fever was less frequent in patients with olfactory and taste dysfunctions \[[@bb0035]\]. Fever was considered a risk factor for severe COVID-19 \[[@bb0015]\]. Anosmia was recently associated with mild-to-moderate COVID-19 and outpatient care \[[@bb0030],[@bb0040]\]. Considering our results and previous evidences, we could hypothesize that patients with olfactory/taste alterations and without associated fever would experience a mild-to-moderate COVID-19, but persistent sensory reduction. Our hypothesis was limited by the absence of severe COVID-19 in our case series.

In conclusion, olfactory and taste dysfunction may be persistent in COVID-19. There is an urgent need for randomized-controlled clinical trials focus on treatment of COVID-19 olfactory and taste alterations.
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[^1]: Fisher exact test and Mann-Whitney U test as needed; Bold = p value inferior to 0.05.
